Effect of dose adjustments on overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX: A post hoc analysis of NAPOLI 3.

Authors: Anjan J Patel, Ashley Ann Laursen, Paul Cockrum, Yutong Liu, Andy Surinach, Whitney Rhodes, Li Zhang, Jia Li, Fiona Maxwell, Zev A. Wainberg, Eileen M. O'Reilly

Published: 2025-01-27

DOI: 10.1200/jco.2025.43.4_suppl.716

Source: Full article

---

Abstract

716